Search Results - Philip E. Empey

Response to "DPYD genotyping panels: Impact of population diversity" by Andrea Gaedigk, Amy J. Turner, Cyrine E. Haidar, Philip E. Empey, Steven M. Offer

Connect to this object online.

Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions by Ruohui Zheng, Guru R. Valicherla, Junmei Zhang, Jeremy Nuttall, Peter Silvera, Leslie J. Marshall, Philip E. Empey, Lisa C. Rohan

Connect to this object online.

Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing by Amy J. Turner, Cyrine E. Haidar, Wenjian Yang, Erin C. Boone, Steven M. Offer, Philip E. Empey, Andrew Haddad, Saba Tahir, Gunter Scharer, Ulrich Broeckel, Andrea Gaedigk

Connect to this object online.

Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping by James C. Coons PharmD, James M. Stevenson PharmD, MS, Ami Patel PharmD, A. J. Conrad Smith MD, Linda Prebehalla BSN, RN, Philip E. Empey PharmD, PhD

Connect to this object online.

Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy by Sony Tuteja, Ramzi G. Salloum, Amanda L. Elchynski, D. Max Smith, Elizabeth Rowe, Kathryn V. Blake, Nita A. Limdi, Christina L. Aquilante, Jill Bates, Amber L. Beitelshees, Amber Cipriani, Benjamin Q. Duong, Philip E. Empey, Christine M. Formea, J. Kevin Hicks, Pawel Mroz, David Oslin, Amy L. Pasternak, Natasha Petry, Laura B. Ramsey, Allyson Schlichte, Sandra M. Swain, Kristen M. Ward, Kristin Wiisanen, Todd C. Skaar, Sara L. Van Driest, Larisa H. Cavallari, Jeffrey R. Bishop, for the IGNITE Pharmacogenetics Working Group

Connect to this object online.